Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07524816) titled 'Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse/Refractory B-cell Lymphoma' on April 3.

Study Type: Observational [Patient Registry]

Primary Sponsor: N.N. Alexandrov National Cancer Centre

Condition: Large B-Cell Lymphoma (LBCL)

Intervention: Other: CAR-T cell therapy

Recruitment Status: Recruiting

Date of First Enrollment: June 1, 2021

Target Sample Size: 76

Countries of Recruitment: Belarus

To know more, visit https://clinicaltrials.gov/study/NCT07524816

Published by HT Digital Content Services with permission from Health Daily Digest....